Tag Archives: eribulin

FDA Approves Halaven for Late-Stage Breast Cancer

Good news for patients with late stage metastatic breast cancer.  The US Food and Drug Administration (FDA) approved eribulin mesylate injection (Halaven; Eisai, Inc) for the treatment of metastatic breast cancer in patients who have received at least 2 prior … Continue reading

Posted in Breast cancer, Cancer | Tagged , , , , , , , , , , , , , , , | Comments Off on FDA Approves Halaven for Late-Stage Breast Cancer

New Hope for Heavily Pretreated Metastatic Breast Cancer Patients

A new chemotherapy agent, eribulin (developed by Eisai), was shown to improve significant survival benefit in heavily pretreated breast cancer, according to the EMBRACE study presented at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting. The new drug … Continue reading

Posted in Breast cancer, Cancer | Tagged , , , , , , , , , | Comments Off on New Hope for Heavily Pretreated Metastatic Breast Cancer Patients